{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T03:05:33Z","timestamp":1779419133929,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes of Health, United States","award":["R01AR079379"],"award-info":[{"award-number":["R01AR079379"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02098-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:44:09Z","timestamp":1775889849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of ovarian cancer cachexia in patients undergoing cytoreductive surgery at the University of Colorado between 2014-2024"],"prefix":"10.1186","volume":"19","author":[{"given":"Eseohi","family":"Ehimiaghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nicklawsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen C.","family":"Torkko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon A.","family":"Mastryoannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah J.","family":"Novinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2098_CR1","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1200\/JCO.2024.42.16_suppl.5616","volume":"42","author":"C Johnson","year":"2024","unstructured":"Johnson C, et al. Disparities in ovarian and uterine cancer in relation to the development of novel therapeutics. J Clin Oncol. 2024;42:5616\u20135616.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2098_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ygyno.2007.06.010","volume":"107","author":"LM Hess","year":"2007","unstructured":"Hess LM, et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;107(2):260\u20135.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2098_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2098_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3892\/ol.2013.1735","volume":"7","author":"T Watanabe","year":"2014","unstructured":"Watanabe T, et al. Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer. Oncol Lett. 2014;7(2):373\u20137.","journal-title":"Oncol Lett"},{"key":"2098_CR5","doi-asserted-by":"publisher","first-page":"101976","DOI":"10.1016\/j.molmet.2024.101976","volume":"86","author":"LJ Delfinis","year":"2024","unstructured":"Delfinis LJ, et al. Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia. Mol Metab. 2024;86:101976.","journal-title":"Mol Metab"},{"issue":"4b","key":"2098_CR6","first-page":"2941","volume":"21","author":"A Gadducci","year":"2001","unstructured":"Gadducci A, et al. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Res. 2001;21(4b):2941\u20137.","journal-title":"Anticancer Res"},{"issue":"2","key":"2098_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/jcsm.12864","volume":"13","author":"Y Luan","year":"2022","unstructured":"Luan Y, et al. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study. J Cachexia Sarcopenia Muscle. 2022;13(2):1289\u2013301.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"2098_CR8","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12094-024-03502-8","volume":"26","author":"A Soria Rivas","year":"2024","unstructured":"Soria Rivas A, et al. SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023). Clin Transl Oncol. 2024;26(11):2866\u201376.","journal-title":"Clin Transl Oncol"},{"key":"2098_CR9","doi-asserted-by":"crossref","unstructured":"Callaway CS et al. Mechanisms of Ovarian Cancer-Associated Cachexia. Endocrinology. 2023;165(1):bqad176.","DOI":"10.1210\/endocr\/bqad176"},{"issue":"9","key":"2098_CR10","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1089\/ars.2011.3965","volume":"15","author":"LA Gilliam","year":"2011","unstructured":"Gilliam LA, St DK, Clair. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011;15(9):2543\u201363.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"2098_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/jcsm.12633","volume":"11","author":"A Dolly","year":"2020","unstructured":"Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know? J Cachexia Sarcopenia Muscle. 2020;11(6):1413\u201328.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"2098_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1188\/02.CJON.235-238","volume":"6","author":"DD Dell","year":"2002","unstructured":"Dell DD. Cachexia in patients with advanced cancer. Clin J Oncol Nurs. 2002;6(4):235\u20138.","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"2098_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","volume":"37","author":"F Pamoukdjian","year":"2018","unstructured":"Pamoukdjian F, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clin Nutr. 2018;37(4):1101\u201313.","journal-title":"Clin Nutr"},{"issue":"2","key":"2098_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejca.2007.11.011","volume":"44","author":"R Sharma","year":"2008","unstructured":"Sharma R, et al. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer. 2008;44(2):251\u20136.","journal-title":"Eur J Cancer"},{"key":"2098_CR15","doi-asserted-by":"crossref","unstructured":"Rickard BP et al. Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers (Basel). 2021;13(17):4318.","DOI":"10.3390\/cancers13174318"},{"key":"2098_CR16","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.2147\/JIR.S332408","volume":"14","author":"GT Ruan","year":"2021","unstructured":"Ruan GT, et al. Association of Systemic Inflammation and Overall Survival in Elderly Patients with Cancer Cachexia - Results from a Multicenter Study. J Inflamm Res. 2021;14:5527\u201340.","journal-title":"J Inflamm Res"},{"issue":"2","key":"2098_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"A Paul","year":"2009","unstructured":"Paul A, Harris RT, Thielke R, Payne J, Gonzalez N. Conde Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"issue":"3","key":"2098_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4480","volume":"37","author":"F Pin","year":"2022","unstructured":"Pin F, et al. RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice. J Bone Min Res. 2022;37(3):381\u201396.","journal-title":"J Bone Min Res"},{"key":"2098_CR19","doi-asserted-by":"crossref","unstructured":"Kim SI et al. Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma. Cancers (Basel), 2020;12(3):559.","DOI":"10.3390\/cancers12030559"},{"issue":"4","key":"2098_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jcsm.12311","volume":"9","author":"F Pin","year":"2018","unstructured":"Pin F, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685\u2013700.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2098_CR21","doi-asserted-by":"crossref","unstructured":"Rajan S et al. Cachexia in gynecologic cancers: The role of biomarkers and cachexia index. Int J Gynaecol Obstet. 2025;171(3):1310\u201316.","DOI":"10.1002\/ijgo.70262"},{"key":"2098_CR22","first-page":"p","volume":"108403","author":"R Di Fiore","year":"2024","unstructured":"Di Fiore R, et al. Sarcopenia in gynaecological cancers. Eur J Surg Oncol. 2025;51(4):108403.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2098_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/jcsm.12107","volume":"7","author":"IJ Rutten","year":"2016","unstructured":"Rutten IJ, et al. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016;7(4):458\u201366.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9990","key":"2098_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249\u201357.","journal-title":"Lancet"},{"key":"2098_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fendo.2019.00809","volume":"10","author":"AL Essex","year":"2019","unstructured":"Essex AL, et al. Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice. Front Endocrinol (Lausanne). 2019;10:809.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2098_CR26","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1002\/jcsm.13035","volume":"13","author":"JR Huot","year":"2022","unstructured":"Huot JR, et al. PGC1alpha overexpression preserves muscle mass and function in cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle. 2022;13(5):2480\u201391.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"2098_CR27","doi-asserted-by":"publisher","first-page":"C139","DOI":"10.1152\/ajpcell.00773.2024","volume":"328","author":"LJ Novinger","year":"2025","unstructured":"Novinger LJ, Weinzierl NM, Bonetto A. Diversity in chemotherapy-induced cachexia. Am J Physiol Cell Physiol. 2025;328(1):C139\u201347.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2098_CR28","doi-asserted-by":"publisher","first-page":"102074","DOI":"10.1016\/j.canep.2021.102074","volume":"76","author":"K Gaitskell","year":"2022","unstructured":"Gaitskell K, et al. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer Epidemiol. 2022;76:102074.","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"2098_CR29","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.3802\/jgo.2017.28.e80","volume":"28","author":"Z Hilal","year":"2017","unstructured":"Hilal Z, et al. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis. J Gynecol Oncol. 2017;28(6):e80.","journal-title":"J Gynecol Oncol"},{"key":"2098_CR30","doi-asserted-by":"crossref","unstructured":"Mangogna A et al. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. J Pers Med. 2023;13(2):284.","DOI":"10.3390\/jpm13020284"},{"issue":"6","key":"2098_CR31","doi-asserted-by":"publisher","first-page":"e001110","DOI":"10.1136\/esmoopen-2020-001110","volume":"5","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open. 2020;5(6):e001110.","journal-title":"ESMO Open"},{"issue":"1","key":"2098_CR32","first-page":"e34389","volume":"15","author":"K Shingala","year":"2023","unstructured":"Shingala K, et al. Racial disparities in survival outcomes of patients with serous epithelial ovarian cancer: a retrospective cohort analysis. Cureus. 2023;15(1):e34389.","journal-title":"Cureus"},{"key":"2098_CR33","doi-asserted-by":"publisher","first-page":"90S","DOI":"10.1097\/01.AOG.0000825572.48793.95","volume":"139","author":"OA Akinyemi","year":"2022","unstructured":"Akinyemi OA, et al. Disparities in outcomes following ovarian cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database (1998\u20132016) [A313]. Obstet Gynecol. 2022;139:90S.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2098_CR34","first-page":"8","volume":"14","author":"R Bachmann","year":"2021","unstructured":"Bachmann R, et al. Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer. Mol Clin Oncol. 2021;14(1):8.","journal-title":"Mol Clin Oncol"},{"issue":"45","key":"2098_CR35","doi-asserted-by":"publisher","first-page":"e17475","DOI":"10.1097\/MD.0000000000017475","volume":"98","author":"X Yin","year":"2019","unstructured":"Yin X, et al. Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis. Med (Baltim). 2019;98(45):e17475.","journal-title":"Med (Baltim)"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02098-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:24:19Z","timestamp":1779416659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02098-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and all experimental protocols in this study were approved by Ethics Committee of the University of Colorado College of Medicine Institutional Review Board (approval number: 24\u20130039).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}